A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level

Summary

The primary objective of the study is to assess pharmacokinetics, dynamics, safety and tolerability of CiVi007 following single and multiple subcutaneous doses in subjects, including those on statin therapy

Timeline

Start

2018-02-07

Primary completion

2020-02-14

Completion

2020-08-18

Drugs

Indications